A new gene therapy approach for Alzheimer's disease
Gene therapy for Alzheimer's disease using virally delivered Abeta variants
This project explores a new gene therapy that uses special proteins to help prevent the harmful buildup in the brain associated with Alzheimer's disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project ID | NIH-11336501 on NIH RePORTER |
What this research studies
Researchers are working on a new gene therapy for Alzheimer's disease, inspired by recent progress in treatments that reduce harmful brain proteins. This therapy uses special, modified proteins that can stop the sticky clumps associated with Alzheimer's from forming and even help break them apart. These helpful proteins are delivered to the brain using a safe virus, similar to how some vaccines work. Early results in animal models show this approach can reduce the problematic protein buildup and slow down disease signs.
Who could benefit from this research
Good fit: Patients diagnosed with Alzheimer's disease, particularly those in early stages, might be ideal candidates for future clinical trials based on this research.
Not a fit: Patients without Alzheimer's disease or those with advanced stages of the disease may not directly benefit from this specific approach.
Why it matters
Potential benefit: If successful, this gene therapy could offer a new way to prevent or slow the progression of Alzheimer's disease by targeting the root cause of protein aggregation.
How similar studies have performed: Recent success with antibody treatments targeting Abeta in Alzheimer's disease suggests that strategies to lower Abeta can be effective, providing a foundation for this novel gene therapy approach.
Where this research is happening
Saint Louis, United States
- Washington University — Saint Louis, United States (Active)
Researchers
- Principal investigator: Jankowsky, Joanna L — Washington University
- Study coordinator: Jankowsky, Joanna L
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.